Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the IOP-lowering efficacy of bimatoprost 0.03% in patients found to be low-responders to latanoprost therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glaucoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bimatoprost 0.03%, Latanoprost

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* · Male or female \> 18 years of age

* Documented low-responder to latanoprost therapy as delineated in the outline above.
* Diagnosis of open-angle glaucoma or ocular hypertension
* Ability to provide informed consent and likely to complete all study visits

Exclusion Criteria

* · Known contraindication to bimatoprost or any component of any study medication

* Uncontrolled systemic disease
* Active ocular disease other than glaucoma or ocular hypertension
* Required use of ocular medications other than the study medications during the study (intermittent use of artificial tear solutions will be permitted)
* History of intraocular surgery within the last 3 months

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Robert Noecker, MD

Role: PRINCIPAL_INVESTIGATOR

UPMC Eye Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dr. Noecker

Pittsburgh, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

5178

Identifier Type: -

Identifier Source: org_study_id